AIM ImmunoTech Inc. (AIM) |
|
0.4001 -0.021 (-5.05%)
|
03-27 16:00 |
|
Open: |
0.41 |
Pre. Close: |
0.4214 |
|
High:
|
0.43 |
Low:
|
0.385 |
|
Volume:
|
116,367 |
Market Cap:
|
19(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:17:12 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.56  One year: 0.64 |
| Support: |
Support1: 0.38 Support2: 0.32 |
| Resistance: |
Resistance1: 0.48 Resistance2: 0.55 |
| Pivot: |
0.46 |
| Moving Average: |
MA(5): 0.42 MA(20): 0.47
MA(100): 0.48 MA(250): 0.66 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 10.6 %D(3): 10.7  |
| RSI: |
RSI(14): 33.4 |
| 52-week: |
High: 1.37 Low: 0.28 |
| Average Vol(K): |
3-Month: 260 (K) 10-Days: 108 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AIM ] has closed below the lower bollinger band by 0.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 29.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.44 - 0.44 |
0.44 - 0.45 |
|
Low:
|
0.4 - 0.41 |
0.41 - 0.41 |
|
Close:
|
0.42 - 0.42 |
0.42 - 0.43 |
|
Company Description |
|
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. |
Headline News |
Mon, 27 Mar 2023
AIM ImmunoTech to Report Full Year 2022 Financial Results on ... - GlobeNewswire
Thu, 23 Mar 2023
100+ Active Companies working to develop 100+ Pipeline ... - Digital Journal
Thu, 16 Mar 2023
AIM ImmunoTech Announces Late-Breaking Presentation at the ... - BioSpace
Tue, 14 Mar 2023
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer ... - PR Newswire
Tue, 14 Mar 2023
Rintatolimod protects mice from Ebola virus infection through double ... - BioWorld Online
Wed, 08 Mar 2023
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
48 (M) |
|
% Held by Insiders
|
4.708e+007 (%) |
|
% Held by Institutions
|
1.3 (%) |
|
Shares Short
|
557 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.975e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-14 |
|
Return on Assets (ttm)
|
839.2 |
|
Return on Equity (ttm)
|
-22.9 |
|
Qtrly Rev. Growth
|
135000 |
|
Gross Profit (p.s.)
|
-0.02 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.31 |
|
Qtrly Earnings Growth
|
-0.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
131.07 |
|
Price to Cash Flow
|
-0.11 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
893760 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-06-10 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
